Pharmacy World and Science

, Volume 18, Issue 5, pp 182–186 | Cite as

Investigation on the chemical stability of erythromycin in solutions using an optimization system

  • M. Brisaert
  • M. Heylen
  • J. Plaizier-Vercammen


Erythromycin, an antibiotic commonly used topically in the treatment of acne, is unstable in solution. The stability is influenced by the pH and by the presence of water. The influence of the pH on the stability of erythromycin was investigated even with the use of dimethyl isosorbide as co-solvent instead of water. The addition of zinc was attempted to ameliorate erythromycin stability as suggested in the literature. To investigate these three factors and their interactions, an optimization technique was carried out consisting of a 23 factorial analysis and a rotative central composite design. The erythromycin solutions were analysed with an HPLC method. The pH and the concentration of dimethyl isosorbide had a significant influence on the stability of erythromycin but the addition of zinc was not a significant factor. Moreover, there was a significant interaction between the pH and dimethyl isosorbide.


Erythromycin Chemical stability Topical solutions HPLC analysis Composite design with 3 factors: pH, conc DMI and conc Zn 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    BurkeB, EadyEA, CunliffeWJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology 1983;108:199–204.Google Scholar
  2. 2.
    AmerMM, TaklaKF. Studies on the stability of some pharmaceutical formulations, V-Stability of erythromycin. Bull Fac Pharm Cairo Univ 1978;15:325–9.Google Scholar
  3. 3.
    TsujiK and GoetzJF. High-performance chromatographic determination of erythromycin. Journal of Chromatography 1978;147:359–67.Google Scholar
  4. 4.
    ExnerJH, ComiteH, DahodS, PochiPE. Topical erythromycin/zinc effect on acne and sebum secretion. Current Therapeutic Research 1983;34:762–7.Google Scholar
  5. 5.
    BrisaertM, VanAckerT and Plaizier-VercammenJA. Onderzoek naar de chemische stabiliteit van erythromycine base in dermatologische lotions. Farmaceutisch Tijdschrift voor België 1994;71:2–5.Google Scholar
  6. 6.
    Leaflet n° 46-1E: Pharmaceuticals ‘Arlasolve’ DMI: dimethyl isosorbide, ICI-surfactants, Everberg, Belgium.Google Scholar
  7. 7.
    CachetTh, KibwageIO, RoetsE, HoogmartensJ. and VanderhaegheH. Optimization of the separation of erythromycin and related substances by high-performance liquid chromatography. Journal of Chromatography 1987;409:91–100.Google Scholar
  8. 8.
    CachetTh, Van denMooterG, HauchecorneR, VinckierC and HoogmartensJ. Decomposition kinetics of erythromycin A in acidic aqueous solutions. International Journal of Pharmaceutics 1989;55:59–65.Google Scholar
  9. 9.
    BoltonS. Pharmaceutical Statistics, Practical and Clinical Applications. 2nd edition revised and expanded. New York: M Dekker, 1990:258–78 and 421–51.Google Scholar
  10. 10.
    LiebermanH, RiegerM and BankerG. Pharmaceutical Dosage Forms: Disperse systems vol. 1. New York: M Dekker, 1988:427–44.Google Scholar
  11. 11.
    MorganE. Chemometrics: Experimental Design. New York John Wiley, 1991:118–121.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • M. Brisaert
    • 1
  • M. Heylen
    • 1
  • J. Plaizier-Vercammen
    • 1
  1. 1.Vrije Universiteit BrusselPharmaceutical Institute, Pharmaceutical Technology and Physical PharmacyBrusselsBelgium

Personalised recommendations